Core Insights - Bio-Techne Corporation (TECH) is scheduled to release its fourth-quarter fiscal 2025 results on August 6, before market opening [1] - The company reported adjusted earnings per share (EPS) of 56 cents in the last quarter, exceeding the Zacks Consensus Estimate by 9.8%, with an average surprise of 6.74% over the past four quarters [1][3] Q4 Estimates for TECH - The Zacks Consensus Estimate for Bio-Techne's revenues is $317.4 million, reflecting a 3.7% increase from the previous year [2] - The EPS estimate suggests a 2% year-over-year improvement to 50 cents [2] Estimate Revision Trend - Earnings estimates for the fourth quarter have remained stable at 50 cents over the past 60 days [3] Factors Impacting Performance - Management noted macro uncertainties, including tariffs and potential NIH budget cuts, which could temporarily slow growth momentum in Q4 [4] - The Protein Sciences division accounted for 72% of net sales in Q3, with potential modest impacts from the divestment of the fetal bovine serum business [5] Growth Drivers - Bio-Techne is expected to benefit from strong demand for research reagents, protein analysis tools, and cell therapy workflow solutions [6] - The FDA's shift away from animal testing may enhance growth for Bio-Techne's organoid solutions, providing ethical and cost-effective alternatives [7] - The protein analytical instrumentation business, particularly the Maurice platform, is anticipated to show strong momentum [8][9] Segment Performance - The Biologics segment's revenue estimate is $225 million, up 5.1% from the previous year, driven by instrument placements and consumables [9] - The Spatial Biology segment is expected to generate $93 million in revenue, a 2.2% increase year-over-year, despite facing NIH funding uncertainties [12] Earnings ESP and Zacks Rank - Bio-Techne has an Earnings ESP of 0.00%, indicating no expected earnings surprise [13] - The company currently holds a Zacks Rank of 4 (Sell) [13]